BioPharmSignal logoBioPharmSignal

Biotech News

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

T2 Biosystems (TTOO)T2 BiosystemsCompany update

Multiple instrument sale demonstrates growing market penetration of T2 Biosystems’ sepsis tests LEXINGTON, Mass. , Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

T2 Biosystems

T2 Biosystems is a medical diagnostics company focused on rapid pathogen detection and bloodstream infection testing. Its business is centered on delivering fast diagnostic information to clinical settings.

Recent company news

TTOOT2 Biosystems2025-01-07 14:00 EST

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

TTOOT2 Biosystems2024-12-18 14:00 EST

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

TTOOT2 Biosystems2024-12-17 14:00 EST

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

TTOOT2 Biosystems2024-12-16 14:00 EST

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

TTOOT2 Biosystems2024-12-09 14:00 EST

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Stock data

Close
0.00 USD
Market cap
—
Exchange
NASDAQ
Sector
MedTech
Location
United States